Sanofi-Aventis/Regeneron's VEGF Trap discontinued in pancreatic cancer
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis and Regeneron Pharmaceuticals have discontinued development of their anti-VEGF drug aflibercept (VEGF Trap) in pancreatic cancer after it failed in its pivotal first-line Phase III trial to improve overall survival, becoming the latest drug casualty in the difficult-to-treat disease.